Book Chapter, though Brief, Begins Connecting the Dots

by Sharon Rondeau

(Mar. 17, 2023) – In a Substack post issued Thursday evening commemorating the third anniversary of the announcement of a “vaccine” clinical trial in response to the spread of the COVID-19 virus in the U.S. and across the globe, investigative journalist John Leake released the fourth chapter of a book he co-authored with Dr. Peter A. McCullough, MD, MPH, titled, “The Courage to Face COVID-19: Preventing Hospitalization and Death While Battling the Bio-Pharmaceutical Complex.”

The clinical trial was announced by then-National Institutes of Allergy and Infectious Diseases (NIAID) Director Dr. Anthony S. Fauci and sought 45 “healthy adult volunteers” between the ages of 18 and 55 in the immediate Seattle, WA area, the press release stated.

NIAID provided funding for the trial, which was conducted by Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle using a product “developed by NIAID scientists and their collaborators at the biotechnology company Moderna, Inc.,” the press release reported.

In the chapter, Leake and McCullough scoff at the claim that the COVID-19 “vaccine” was developed at “record speed,” writing:

Record speed indeed. The causal agent of COVID-19 wasn’t known until Chinese researchers announced they’d identified it on January 7, 2020. A draft copy of the genome was made available to researchers on January 11, and the first reported U.S. case was on January 21 in Seattle.[ii] The WHO did not declare COVID-19 a pandemic until March 11—five days before NIAID and Moderna began their human clinical trial.[iii] Clearly this partnership had been developing their new mRNA vaccine technology against coronaviruses such as SARS and MERS for some time. According to Moderna’s website, the company had been working on mRNA technology for a decade, investing tens of millions in its development. Now it seemed they had an opportunity to deploy it on a global scale.[iv]

The authors further noted that “Dr. Fauci did not mention in the announcement that the NIH (a government research funding institution) had not only invested in the vaccine for promoting public health, but also claimed to co-own the patent and therefore stood to share the royalties from its commercial exploitation.[v]“

In late 2021, Moderna sued the National Institutes of Health (NIH), the NAIAD’s parent agency, over patent ownership of the jointly-developed COVID vaccine product. Just recently, Moderna agreed to compensate the NIH for its role in producing the “Covid Vaccine Technique” employed in the final product, mRNA-1273, The New York Times reported.

However, Moderna and Pfizer, another COVID vaccine behemoth, are locked in a separate legal battle over alleged “patent infringement.”

The authors then connect the COVID-19 “pandemic” declaration with “the Event 201 Pandemic Simulation” which took place in October 2019, approximately four months before SARS-COV-2 was identified as having infected its first U.S. victim in Snohomish County, WA.

Event 201 was co-sponsored by the Center for Health Security of the Bloomberg School of Public Health, Johns Hopkins University; the Bill & Melinda Gates Foundation, which would heavily promote and profit from the worldwide distribution of COVID-19 “vaccines”; and the World Economic Forum (WEF), promoter of “the Great Reset” as the world navigated the chaos of the “pandemic” declared by the World Health Organization (WHO), a subsidiary of the United Nations.

In a statement dated January 24, 2020, the Center for Health Security wrote:

In October 2019, the Johns Hopkins Center for Health Security hosted a pandemic tabletop exercise called Event 201 with partners, the World Economic Forum and the Bill & Melinda Gates Foundation. Recently, the Center for Health Security has received questions about whether that pandemic exercise predicted the current novel coronavirus outbreak in China. To be clear, the Center for Health Security and partners did not make a prediction during our tabletop exercise. For the scenario, we modeled a fictional coronavirus pandemic, but we explicitly stated that it was not a prediction. Instead, the exercise served to highlight preparedness and response challenges that would likely arise in a very severe pandemic. We are not now predicting that the nCoV-2019 outbreak will kill 65 million people. Although our tabletop exercise included a mock novel coronavirus, the inputs we used for modeling the potential impact of that fictional virus are not similar to nCoV-2019.

The Center for Epidemic Preparedness Innovation, or “CEPI,” was launched at the World Economic Forum’s 2017 meeting in Davos, Switzerland, an annual event, with a mission of, “New vaccines for a safer world.”

The organization also strives to transcend “a destructive legacy of racism,” its website states, as well as “to affecting [sic] positive change in the workplace and the principles of equality, inclusion, and non-discrimination guide all our internal and external policies.”

CEPI is funded in part by the Bill & Melinda Gates Foundation; the “global charitable foundation” Wellcome Trust; many national governments; the “Goldman-Sachs Gives” charity and the United Nations’ “COVID-19 Solidarity Response Fund.”

Sir Jeremy Farrar, previously Wellcome’s director, was recently named “chief scientist” at the World Health Organization, a United Nations subsidiary.

CEPI’S 2016 “Preliminary Business Plan,” a reference to which Leake and McCullough conclude their chapter, states that “Epidemics of emerging infectious diseases, such as SARS and Ebola, threaten life, health and prosperity. They are among the world’s most pressing health security issues.”

Page 55 states:

A DNA vaccine against SARS expressing the S protein was put into a Phase I trial by the VRC. It elicited neutralizing antibodies after three doses as well as CD4+ T cell response.
CD8+ responses were seen in a minority of subjects. Sinovac tested an inactivated virus vaccine. Fortunately, there are multiple other candidates besides those from the VRC.
Prominent among them is a stable S trimer nanoparticle produced by Novavax, a plasmid DNA vaccine for the S protein produce by Inovio in collaboration with the GeneOne company in South Korea, which is in Phase 1 trial, and several vectored vaccines, including ones based on S or S1 expressed by adenoviruses, chimp adenovirus, measles, and MVA, all of which have shown immunogenicity in animals and some of which have also tested positively for protection. The organizations testing these vaccines are based in China, the
UK, the US and Germany. It appears that neutralizing antibodies are a correlate of protection, with CD8+ T cells useful if infection takes place, and that multiple known
manufacturing platforms are available.

According to the NIH:

mRNA acts as a cellular messenger. DNA, which is stored in a cell’s nucleus, encodes the genetic information for making proteins. mRNA transfers a copy of this genetic information outside of the nucleus, to a cell’s cytoplasm, where it is translated into amino acids by ribosomes and then folded into complete proteins. mRNA is a short-lived molecule, meaning it degrades easily and does not last long inside cells.

By injecting cells with a synthetic mRNA that encodes a viral spike protein, an mRNA vaccine can direct human cells to make a viral spike protein and evoke an immune response without a person ever having been exposed to the viral material.

These viral spike proteins, or antigens, normally coat the surface of the virus and are recognized by antibodies and other immune cells that prepare and protect the body against the virus. If a person is later exposed to the virus, antibodies and other parts of the immune system can recognize and attack the virus before it can infect healthy cells or cause illness.